论文部分内容阅读
目的:探讨IL-10治疗对哮喘鼠血清IL-17及IgE水平的影响。方法:制备20只小鼠哮喘模型,随机分为治疗组、哮喘组,前者使用rmIL-10治疗,后者未予治疗,用ELISA双抗体夹心法测定治疗组和哮喘组血清IL-17和IgE的水平。以10只健康小鼠为对照组。结果:与对照组比较,哮喘组IL-17和IgE水平较高,差异均有统计学意义(P<0.05);经rmIL-10治疗后,治疗组的血清IL-17、IgE的水平明显低于哮喘组水平,其差异有统计学意义(P<0.05);治疗组治疗后IL17和和IgE检测值与正常组水平差异无统计学意义(P>0.05)。结论:IL-10能够降低哮喘小鼠血清的IL-17和IgE水平,可望在治疗人类哮喘中发挥一定的作用。
Objective: To investigate the effect of IL-10 on serum IL-17 and IgE levels in asthmatic mice. Methods: Twenty mouse models of asthma were randomly divided into treatment group and asthma group. The former was treated with rmIL-10 and the latter was untreated. Serum IL-17 and IgE s level. Ten healthy mice were used as control group. Results: The levels of IL-17 and IgE in the asthma group were significantly higher than those in the control group (P <0.05). After treatment with rmIL-10, the levels of serum IL-17 and IgE in the asthma group were significantly lower (P <0.05). There was no significant difference between IL17 and IgE levels in the treatment group and the normal group (P> 0.05). Conclusion: IL-10 can reduce the serum levels of IL-17 and IgE in asthmatic mice and is expected to play a role in the treatment of human asthma.